SCHERING BEGINS TRIALS OF ZK-EPO

A A

Schering has launched two Phase II trials in the U.S. and Canada to evaluate ZK-EPO, a pending breast and ovarian cancer treatment.

The breast cancer trial will be an open-label study at about 20 sites in the U.S. and Canada. Patients with metastatic breast cancer who failed on other chemotherapy options will receive ZK-EPO every three weeks.

In the second study, patients with recurrent ovarian cancer will be administered ZK-EPO in combination with carboplatin after first-line treatment with platinum-based chemotherapy.